Plasmaperfusion on Triptophan Columns Can Improve the Clinical Outcome of Patients Affected with Myasthenia Gravis

References

• AAEM Quality Assurance Committee. American Association of Electrodiagnostic Medicine. Literature review of the usefulness of repetitive nerve stimulation and single fiber EMG in the electrodiagnostic evaluation of patients with suspected myasthenia gravis or Lambert‐Eaton myasthenic syndrome. Muscle Nerve 2001; 24(9)1239–1247
   PubMed Web of Science ®Google Scholar
• Batocchi A. P., Evoli A., Di Schino C., Tonali P. Therapeuthic apheresis in myasthenia gravis. Ther. Apher. 2000; 4(4)275–279
   PubMedGoogle Scholar
• Bruck W., Neubert K., Berger T., Weber J. R. Clinical, radiological, immunological and pathological findings in inflammatory CNS demyelination‐possible markers for an antibody‐mediated process. Mult. Scler. 2001; 7(3)173–177
   PubMed Web of Science ®Google Scholar
• Chia D., Barnett E. V., et al. Quantitation and characterization of soluble immune complexes precipitated from sera by polyethylene glycol. Clin. Exp. Immunol. 1979; 37: 399–400
   PubMed Web of Science ®Google Scholar
• de Andres C., Anaya F., Gimenez‐Roldan S. Plasma immunoadsorption treatment of malignant multiple sclerosis with severe and prolonged relapses. Rev. Neurol. 2000; 30(7)601–605
   PubMed Web of Science ®Google Scholar
• Hadden R. D., Gregson N. A. Guillain‐Barre syndrome and Campylobacter jejuni infection. Symp. Ser. Soc. Appl. Microbiol. 2001; 30: 145S–154S
   Google Scholar
• Haupt W. F. Recent advances of therapeutic apheresis in Guillain Barrè syndrome. Ther. Apher. 2000; 4(4)271–274
   PubMedGoogle Scholar
• Haupt W. F., Birkmann C., van der Ven C., Pawlik J. Apheresis and selective adsorption plus immunoglobulin treatment in Guillain Barrè syndrome. Ther. Apher. 2000; 4(3)198–200
   PubMedGoogle Scholar
• Haupt W. F., Rosenow F., van der Ven C., Birkman C. Immunoadsorption in Guillain Barrè syndrome and myasthenia gravis. Ther. Apher. 2000; 4(3)195–197
   PubMedGoogle Scholar
• Hughes R. A., Hadden R. D., Gregson N. A., Smith K. J. Pathogenesis of Guillain‐Barre syndrome. J. Neuroimmunol. 1999; 100(1–2)74–97
   PubMed Web of Science ®Google Scholar
• Lindstrom J. An easy for antibodies to human acetylcholine receptor in serum from patient with myastenia gravis. Clin. Immunol. Immunopathol. 1977; 7: 36–43
   PubMedGoogle Scholar
• Malcheski P. S., Horiuchi T., Usami M., Emura M., Nose J. Blood detoxification by membrane plasma filtration. Int. J. Art. Org. 1986; 9(5)349–354
   PubMed Web of Science ®Google Scholar
• Morosetti M., Meloni C., Iani C., Caramia M., Galderisi C., Palombo G., Gallucci M. T., Bernardi G., Casciani C. U. Plasmapheresis in severe forms of myasthenia gravis. Artif. Organs 1998; 22(2)129–134
   PubMed Web of Science ®Google Scholar
• Nakaji S., Oka K., Tanihara M., Takakura K., Takamori M. Development of a specific immunoadsorbent containing immobilized synthetic peptide of acetylcholine receptor for treatment of myasthenia gravis. Ther. Apher. 2000; 4(2)124–126
   PubMedGoogle Scholar
• Nevo Y. Childhood chronic inflammatory demyelinating polyneuropathy. Eur. J. Paediatr. Neurol. 1998; 2(4)169–177
   PubMedGoogle Scholar
• Palace J., Vincent A., Beeson D. Myasthenia gravis: diagnostic and management dilemmas. Curr. Opin. Neurol. 2001; 14(5)583–589
   PubMed Web of Science ®Google Scholar
• Ross E. A., Branham M. L., Tebett I. R. High mass clearance of autoantibodies from a murine model of lupus nephritis by immunoadsorption using star‐configured polyethylene glycols. J. Biomed. Mater. Res. 2001; 55(1)114–120
   PubMed Web of Science ®Google Scholar
• Sghirlanzoni A., Pelucchetti D., et al. Myasthenia gravis: prolonged treatment with steroids. Neurology 1984; 34: 170–174
   PubMed Web of Science ®Google Scholar
• Steimnam L. Immunotherapy of multiple sclerosis: the end of the beginning. Curr. Opin. Immunol. 2001; 13(5)597–600
   PubMed Web of Science ®Google Scholar
• Tagawa, et al. Ability to remove immunoglobulins and anti‐ganglioside antibodies by plasma exchange, DFP and immunoadsorption. J. Neurol. Sci. 1998; 157(1)90–95
   PubMed Web of Science ®Google Scholar
• Takahashi I., Sawaishi Y., Takeda O., Enoki M., Takada G. Childhood multiple sclerosis treated with plasmapheresis. Pediatr. Neurol. 1997; 17(1)83–87
   PubMed Web of Science ®Google Scholar
• Vedanarayanan V. V., Chaudhry V. Guillain Barrè syndrome: recent advances. Indian J. Pediatr. 2000; 67(9)635–646
   PubMedGoogle Scholar
• Vincent A., Palace J., Hilton‐Jones D. Myasthenia gravis. Lancet 2001; 357(9274)2122–2128
   PubMed Web of Science ®Google Scholar
• Wandinger K. P., Sturzebecher C. S., Bielekova B., et al. Complex immunomodulatory effects of interferon‐beta in multiple sclerosis include the upregulation of T helper 1‐associated marker genes. Ann. Neurol. 2001; 50(3)349–357
   PubMed Web of Science ®Google Scholar
• Yamavaki N. Artificial receptors and their clinical applications to blood purification therapy. J. Synt. Org. Chem. 1985; 43: 1024
   Web of Science ®Google Scholar
• Yuki N., Susuki K., Hirata K. Ataxic form of Guillain‐Barr syndrome associated with anti‐GD1b IgG antibody. J. Neurol. Neurosurg. Psychiatry 2000; 69(1)136–137
   PubMed Web of Science ®Google Scholar